Dana-Farber Cancer Institute researchers reported the development of a systematic platform for discovering molecular-glue degraders, aimed at redirecting a cell’s protein-disposal machinery toward disease-associated targets. The team also described its first metabolically activated molecular glue, outlining a potential way to control when and where degradation occurs. Mechanistically, molecular glues are small molecules that induce or stabilize a new interaction between an endogenous protein target and an E3 ligase component, enabling degradation. The work positions these compounds as drug-like alternatives to traditional degradation approaches by expanding the pool of proteins that can be eliminated. For translational oncology, the outcome is a practical one: a discovery framework designed to be repeatable could accelerate early hit-to-lead cycles and broaden therapeutic coverage.